Postpartum Bleeding Drug Market Scope
Postpartum hemorrhage (PPH) or postpartum bleeding is a condition representing significant blood loss after the child birth in adult females or new mothers. Postpartum hemorrhage (PPH) for vaginal birth is 500ml wherein for cesarean, around 1,000ml of blood loss. In severe case, the hemorrhage may lead to hemorrhage or shock from blood loss, as an outcome of rise in the normal plasma volume. Postpartum Bleeding Drug are the prescribed medications to treat the blood loss. Some uterotonic agents’ such as oxytocin, prostaglandins, ergot alkaloids, and others are used to stimulate the contraction of the myometrium, which limits the spiral arteries resulting into reduction in the blood flow through uterus.
The Postpartum Bleeding Drug market study is segmented by Type (Oxytocin, Methergine, Hemabate, Misoprostol, Carboprost, Tranexamic acid and Others) and major geographies with country level break-up.
Research Analyst at AMA estimates that Players concentration is mainly in United States Players will contribute to the maximum growth of Global Postpartum Bleeding Drug market throughout the predicted period.
Lupin Pharmaceuticals (India), GlaxoSmithKline plc. (United Kingdom), Pfizer Inc. (United States), BD (United States), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), Baxter Healthcare Corporation (United States), Novartis AG (Switzerland), Par Pharmaceuticals (United States) and Utah Medical Products (United States) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Postpartum Bleeding Drug market by Type, Application and Region.
On the basis of geography, the market of Postpartum Bleeding Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In May 2018, Granules Pharmaceuticals, Inc., a part of Granules India Ltd., entered into partnership with the West-Ward Pharmaceuticals Corp., a subsidiary of Hikma Pharmaceuticals PLC to introduce the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine.
In July 2019, Dr. Reddy’s Laboratories introduced Carboprost Tromethamine Injection USP, 250mcg/mL (1mL), a generic version of Hemabate (Pfizer) as a Competitive Generic Therapy (CGT) for postpartum bleeding.
- Ongoing research for development of new drug formulations
- Growing prevalence of postpartum related deaths
- Favourable government strategies to prevent postpartum hemorrhage
- Side effects associated with different postpartum bleeding drug
- Availability of alternative treatments to treat postpartum hemorrhage
Key Target AudienceManufacturer of Delivery Hemorrhage Drugs
Frequently asked questions:1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Postpartum Bleeding Drug Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.